Key messages from scientific research that's ready to be acted on
Got It, Hide thisGuirguis-Blake JM, Beil TL, Senger CA, et al. Ultrasonography screening for abdominal aortic aneurysms: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2014;160:321-9.
Does an invitation to screening for abdominal aortic aneurysm (AAA) in people who have no symptoms reduce ruptures or death from ruptures?
The aorta is the major blood vessel that supplies blood to the body and runs from the heart to the abdomen. An AAA is a weakening in the wall of the aorta. If an AAA ruptures, it causes internal bleeding, which can be fatal unless successfully treated with emergency surgery. People may not know that they have an AAA because they don’t always cause symptoms. Screening of people who don’t have symptoms using ultrasound can identify those with AAAs who can then be monitored more closely or treated, depending on the size of the AAA. Some people who have an AAA detected may choose to have elective surgery.
The researchers did a systematic review, searching for studies of screening for AAA published up to September 2013. They found 4 randomized controlled trials of 137,214 people (average age 68 to 73 years, 41% to 100% men). The key features of the studies were as follows:
The quality of the evidence was good for 2 trials and fair for 2 trials.
63% to 80% of those invited to have screening actually had an ultrasound.
Ultrasound screening for AAA:
In elderly people who do not have symptoms, an invitation to screening for abdominal aortic aneurysm using ultrasound can reduce death from AAA.
Outcomes | Number of trials | Ultrasound screening | No invitation to screening | Risk of events at up to 15 years |
Death from AAA or after AAA surgery | 4 trials (137,214 people) | Trial A: 0.7% Trial B: 0.3% | Trial A: 1.1% Trial B: 0.9% | Trial A: reduced by 4 per 1,000 people Trial B: reduced by 6 per 1,000 people No reduction in 2 trials |
AAA rupture | 2 trials (83,575 people) | Trial A: 0.8%
| Trial A: 1.4%
| Trial A: reduced by 6 per 1,000 people No reduction in the other trial |
Support for the Portal is largely provided by the Labarge Optimal Aging Initiative. AGE-WELL is a contributing partner. Help us to continue to provide direct and easy access to evidence-based information on health and social conditions to help you stay healthy, active and engaged as you grow older. Donate Today.